Stock NBIX NEUROCRINE BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-26 EDT 		5-day change 1st Jan Change
136 USD -1.28% Intraday chart for Neurocrine Biosciences, Inc. +3.02% +3.21%
04-24 Wells Fargo Upgrades Neurocrine Biosciences to Overweight From Equalweight, Price Target is $170 MT
04-24 Neurocrine Biosciences, Inc. Launches What the C@H! Educational Initiative to Support Congenital Adrenal Hyperplasia Community CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Neurocrine Biosciences, Inc. Launches What the C@H! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
Neurocrine Biosciences, Inc. Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
Sentia Medical Sciences Inc. and Neurocrine Biosciences, Inc. Extend Research Collaboration to Discover Novel CRF Peptides
Neurocrine Biosciences Doses First Patient in Phase 2 Depressive Disorder Study
Neurocrine Biosciences, Inc. Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
Neurocrine Biosciences Starts Phase 1 Trial of Investigational Neuropsychiatric Drug
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
Neurocrine Biosciences Insider Sold Shares Worth $5,576,710, According to a Recent SEC Filing
Neurocrine Biosciences Insider Sold Shares Worth $420,419, According to a Recent SEC Filing
Neurocrine Biosciences Insider Sold Shares Worth $922,632, According to a Recent SEC Filing
Neurocrine Biosciences Insider Sold Shares Worth $1,085,388, According to a Recent SEC Filing
Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
Neurocrine Biosciences Insider Sold Shares Worth $1,987,047, According to a Recent SEC Filing
Neurocrine Biosciences Insider Sold Shares Worth $376,700, According to a Recent SEC Filing
Neurocrine Biosciences Insider Sold Shares Worth $313,530, According to a Recent SEC Filing
Neurocrine Biosciences Insider Sold Shares Worth $290,968, According to a Recent SEC Filing
Neurocrine Biosciences Insider Sold Shares Worth $359,041, According to a Recent SEC Filing
Neurocrine Biosciences Insider Sold Shares Worth $737,271, According to a Recent SEC Filing
Neurocrine Biosciences Insider Sold Shares Worth $270,284, According to a Recent SEC Filing
Neurocrine Biosciences Insider Sold Shares Worth $352,612, According to a Recent SEC Filing
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NBIX Stock
  4. News Neurocrine Biosciences, Inc.
  5. Other languages